🔗 Share this article

While America undertakes unprecedented adjustments to its vaccination schedules, one figure appears somewhat surprisingly: Høeg, a Danish American physician and public health researcher who first made her name by casting doubt on coronavirus vaccines during the pandemic and has concentrated on alleged deaths following COVID-19 vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Immunization Schedule

Agency leaders had intended to reveal major changes to the pediatric vaccination calendar in December, bringing the US with the Danish national calendar, according to reports – a significant shift that would put the US at odds with much of the international standard with little proof for improved outcomes. The planned update has been pushed back until the new year.

In place of the top vaccines chief, Høeg is listed to speak at the event. She was newly appointed interim head of the FDA’s CDER, the fifth individual to run the division this calendar year.

A New Direction at the Regulatory Body

This interim role might represent a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it signals a renewed priority upon dismantling previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for ending specific pediatric immunization guidelines in the US in order to be more like the Danish model, a country with nationalized medicine and a population approximately the size of the state of Wisconsin.

In her initial public appearances, she has continued to focus on immunizations – typically the purview of Dr. Prasad, head of the FDA’s vaccine center – instead of medication approval.

Doubts Over Expertise

Dr. Høeg has no obvious background in drug development, regulation or management, which has been customary for former heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the commissioner and the vaccine center since March.

“She doesn’t seem to have the necessary background” for running the drug-regulation department, said a neurologist and psychiatrist. “She has not conducted a clinical trial. She is not versed in leading a sizeable institution. She is not an expert in drug approvals.”

Former heads of the center would “grasp regulatory frameworks and the research of pharmaceutical innovation”, noted a former acting FDA commissioner. “Clearly, she lacks the sort of resume that prior appointees who led CBER have had.”

The drug center has an immense portfolio at the agency, Woodcock stated.

“Many people just focuses on the novel medication approvals, but the generic program approves a multitude of generic medications. There is also a biologic copycat branch, non-prescription drug unit and more, and all of those need to be managed,” Dr. Woodcock said. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Furthermore, a significant leadership component to the position, which supervises more than 5,000 staff members. “It is a massive management job, if you do it right,” Woodcock added.

Agency Reaction and Contentious Programs

Regarding inquiries about Høeg’s qualifications and whether this appointment signifies more teamwork among agency officials on immunizations, a representative stated that the “concerns stem from inaccurate premises”.

“This background matches the functions of her role,” the official said, pointing to the time Høeg spent guiding the FDA commissioner on “pharmaceutical safety and approval science, including computational safety modeling and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's recently launched priority voucher program, a disputed one-day therapy clearance system that allegedly troubled her preceding directors. “How are these drugs being picked for this voucher program? Who takes the decisions?” Dr. Howard questioned. “There’s a lot of lack of transparency occurring at the agency right now.”

Broadly speaking, he remarked, “the Food and Drug Administration seems to be moving towards less stringent rules of pharmaceuticals, except for shots.”

Public History on Vaccines

Regarding vaccines, Høeg has a clearer, if concerning, history, critics said. She released a study using unverified crowd-sourced reports to determine the incidence of heart inflammation following Covid immunization. She consulted for the Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccines are more dangerous than they are.

Included in her “desired changes” for the new administration featured altering guidelines for new vaccines and discontinuing “unnecessary” immunizations, she stated following the vote on a podcast. At the FDA, Høeg has according to sources suggested preventing young men from receiving Covid vaccinations.

“She is an all-around ideologue who begins with her beliefs and works backwards to accommodate the science in a highly deceptive, untruthful manner,” Howard said.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with fellow contrarians, {like|